In humans, a plasma proteomic analysis of a small CML patient cohort treated 3 months with dasatinib revealed increased IFNγ and decreased IL-10 plasma levels. This evidence concerns the gene IL10 and chronic myelogenous leukemia, BCR-ABL1 positive.